{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,31]],"date-time":"2026-01-31T00:14:59Z","timestamp":1769818499372,"version":"3.49.0"},"reference-count":24,"publisher":"Oxford University Press (OUP)","issue":"1","license":[{"start":{"date-parts":[[2020,10,10]],"date-time":"2020-10-10T00:00:00Z","timestamp":1602288000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2021,1,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Purpose<\/jats:title>\n                  <jats:p>Ledipasvir\/sofosbuvir is an oral combination therapy containing fixed doses of direct-acting antiviral agents indicated for the treatment of hepatitis C virus (HCV) infection. Currently there are limited data on the clinical efficacy of crushed ledipasvir\/sofosbuvir administered via feeding tube.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Summary<\/jats:title>\n                  <jats:p>This case report discusses the successful treatment of chronic HCV genotype 1b infection with crushed ledipasvir\/sofosbuvir administered through a percutaneous endoscopic gastrostomy (PEG) tube in a patient with human immunodeficiency virus (HIV) coinfection and high-grade sarcoma who had severe swallowing difficulties. The patient received crushed ledipasvir\/sofosbuvir daily for a total of 12 weeks. At 12 weeks the patient had achieved a sustained virologic response.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusion<\/jats:title>\n                  <jats:p>Currently, ledipasvir\/sofosbuvir is available only as a tablet, with limited pharmacokinetic data available to guide clinicians on use of the fixed-dose combination medication in crushed form. This case report highlights our experience treating a patient with HCV\/HIV coinfection through administration of crushed ledipasvir\/sofosbuvir via PEG tube, which we found to be a safe and effective therapeutic option.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/ajhp\/zxaa328","type":"journal-article","created":{"date-parts":[[2020,10,10]],"date-time":"2020-10-10T07:24:31Z","timestamp":1602314671000},"page":"36-40","source":"Crossref","is-referenced-by-count":3,"title":["Treatment of chronic hepatitis C virus infection with crushed ledipasvir\/sofosbuvir administered through a percutaneous endoscopic gastrostomy tube in a patient with HIV coinfection"],"prefix":"10.1093","volume":"78","author":[{"given":"Vanessa","family":"Huffman","sequence":"first","affiliation":[{"name":"Department of Pharmacy, Memorial Hospital West, Memorial Healthcare System, Pembroke Pines, FL"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Diana C","family":"Andrade","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Memorial Hospital West, Memorial Healthcare System, Pembroke Pines, FL"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elizabeth","family":"Sherman","sequence":"additional","affiliation":[{"name":"Division of Infectious Disease, Memorial Regional Hospital, Memorial Healthcare System, Hollywood, FL"},{"name":"College of Pharmacy, Nova Southeastern University, Fort Lauderdale, FL"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jianli","family":"Niu","sequence":"additional","affiliation":[{"name":"Office of Human Research, Memorial Healthcare System, Hollywood, FL"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paula A","family":"Eckardt","sequence":"additional","affiliation":[{"name":"Division of Infectious Disease, Memorial Regional Hospital, Memorial Healthcare System, Hollywood, FL"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2020,10,10]]},"reference":[{"key":"2020121603535034000_CIT0001","author":"National Notifiable Diseases Surveillance System, Centers for Disease Control and Prevention"},{"key":"2020121603535034000_CIT0002","doi-asserted-by":"crossref","first-page":"920","DOI":"10.1017\/S0950268818000766","article-title":"HIV and viral hepatitis coinfection analysis using surveillance data from 15 US states and two cities","volume":"146","author":"Bosh","year":"2018","journal-title":"Epidemiol Infect."},{"key":"2020121603535034000_CIT0003","doi-asserted-by":"crossref","first-page":"562","DOI":"10.1086\/321909","article-title":"Influence of human immunodeficiency virus infection on the course of hepatitis C virus infection: a meta-analysis","volume":"33","author":"Graham","year":"2001","journal-title":"Clin Infect Dis."},{"key":"2020121603535034000_CIT0004","doi-asserted-by":"crossref","first-page":"1198","DOI":"10.1016\/S0140-6736(10)62001-6","article-title":"Increasing burden of liver disease in patients with HIV infection","volume":"377","author":"Joshi","year":"2011","journal-title":"Lancet."},{"key":"2020121603535034000_CIT0005","doi-asserted-by":"crossref","first-page":"670","DOI":"10.4254\/wjh.v10.i10.670","article-title":"Era of direct acting anti-viral agents for the treatment of hepatitis C","volume":"10","author":"Ahmed","year":"2018","journal-title":"World J Hepatol."},{"key":"2020121603535034000_CIT0006","author":"American Association for the Study of Liver Diseases and Infectious Diseases Society of America","year":"2018"},{"key":"2020121603535034000_CIT0007","volume-title":"Copegus [package insert]","year":"2011"},{"key":"2020121603535034000_CIT0008","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1056\/NEJMoa032653","article-title":"Peginterferon alfa-2a plus ribavirin versus interferon alfa-2a plus ribavirin for chronic hepatitis C in HIV-coinfected persons","volume":"351","author":"Chung","year":"2004","journal-title":"N Engl J Med."},{"key":"2020121603535034000_CIT0009","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1056\/NEJMoa040842","article-title":"Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection in HIV-infected patients","volume":"351","author":"Torriani","year":"2004","journal-title":"N Engl J Med."},{"key":"2020121603535034000_CIT0010","doi-asserted-by":"crossref","first-page":"F27","DOI":"10.1097\/00002030-200409030-00003","article-title":"Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for treatment of HIV\/HCV co-infected patients","volume":"18","author":"Laguno","year":"2004","journal-title":"AIDS."},{"key":"2020121603535034000_CIT0011","doi-asserted-by":"crossref","first-page":"2839","DOI":"10.1001\/jama.292.23.2839","article-title":"Pegylated interferon alfa-2b vs standard interferon alfa-2b, plus ribavirin, for chronic hepatitis C in HIV-infected patients: a randomized controlled trial","volume":"292","author":"Carrat","year":"2004","journal-title":"JAMA."},{"key":"2020121603535034000_CIT0012","doi-asserted-by":"crossref","first-page":"972","DOI":"10.1089\/aid.2007.0011","article-title":"Role of weight-based ribavirin dosing and extended duration of therapy in chronic hepatitis C in HIV-infected patients: the PRESCO trial","volume":"23","author":"N\u00fa\u00f1ez","year":"2007","journal-title":"AIDS Res Hum Retroviruses."},{"key":"2020121603535034000_CIT0013","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1111\/hiv.12086","article-title":"Virological response rates for telaprevir-based hepatitis C triple therapy in patients with and without HIV coinfection","volume":"15","author":"Martel-Laferri\u00e8re","year":"2013","journal-title":"HIV Med."},{"key":"2020121603535034000_CIT0014","doi-asserted-by":"crossref","first-page":"974","DOI":"10.1002\/hep.26096","article-title":"Anemia during treatment with peginterferon alfa-2b\/ribavirin and boceprevir: analysis from the serine protease inhibitor therapy 2 (SPRINT-2) trial","volume":"57","author":"Sulkowski","year":"2013","journal-title":"Hepatology."},{"key":"2020121603535034000_CIT0015","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1007\/s40265-018-0864-z","article-title":"Ledipasvir\/sofosbuvir: a review in chronic hepatitis C","volume":"78","author":"Scott","year":"2018","journal-title":"Drugs."},{"key":"2020121603535034000_CIT0016","doi-asserted-by":"crossref","first-page":"730","DOI":"10.1111\/jcpt.12713","article-title":"Successful treatment of chronic hepatitis C infection with crushed elbasvir\/grazoprevir administered via percutaneous endoscopic gastrostomy tube","volume":"43","author":"Yap","year":"2018","journal-title":"J Clin Pharm Ther."},{"issue":"6","key":"2020121603535034000_CIT0017","doi-asserted-by":"crossref","first-page":"588","DOI":"10.1007\/s12328-019-00997-5","article-title":"Successful treatment of chronic hepatitis C virus infection with crushed glecaprevir\/pibrentasvir administered via a percutaneous endoscopic gastrostomy tube: case report and review of the literature","volume":"12","author":"Tanaka","year":"2019","journal-title":"Clin J Gastroenterol."},{"issue":"5","key":"2020121603535034000_CIT0018","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1177\/0897190017731245","article-title":"Treatment of chronic hepatitis C virus Infection with crushed ledipasvir\/sofosbuvir administered via a percutaneous endoscopic gastrostomy tube","volume":"31","author":"Jindracek","year":"2018","journal-title":"J Pharm Pract."},{"key":"2020121603535034000_CIT0019","doi-asserted-by":"crossref","first-page":"1761","DOI":"10.2146\/ajhp170452","article-title":"Administration of crushed ledipasvir-sofosbuvir tablets via gastrostomy button in a patient coinfected with HIV and hepatitis C virus","volume":"74","author":"Fulco","year":"2017","journal-title":"Am J Health-Syst Pharm."},{"key":"2020121603535034000_CIT0020","volume-title":"Harvoni [package insert]","year":"2019"},{"key":"2020121603535034000_CIT0021","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1080\/15284336.2016.1248625","article-title":"Clinical experience with dolutegravir\/abacavir\/lamivudine in HIV-HCV co-infected patients treated with a sofosbuvir-based regimen-safety and efficacy","volume":"17","author":"Johnson","year":"2016","journal-title":"HIV Clin Trials."},{"key":"2020121603535034000_CIT0022","first-page":"94","article-title":"Crushed dolutegravir\/abacavir\/lamivudine given via nasogastric tube in gastric outlet obstruction caused by cancer resulted in rapid viral load suppression","volume":"31","author":"Chrdle","year":"2018","journal-title":"Int J STD AIDS."},{"key":"2020121603535034000_CIT0023","doi-asserted-by":"crossref","first-page":"2430","DOI":"10.1093\/jac\/dky191","article-title":"Crushing of dolutegravir combination tablets increases dolutegravir exposure","volume":"73","author":"Roskam-Kwint","year":"2018","journal-title":"J Antimicrob Chemother."},{"key":"2020121603535034000_CIT0024","author":"American Association for the Study of Liver Diseases and Infectious Diseases Society of America"}],"container-title":["American Journal of Health-System Pharmacy"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/ajhp\/article-pdf\/78\/1\/36\/34923600\/zxaa328.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/academic.oup.com\/ajhp\/article-pdf\/78\/1\/36\/34923600\/zxaa328.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,12,16]],"date-time":"2020-12-16T08:56:17Z","timestamp":1608108977000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ajhp\/article\/78\/1\/36\/5920509"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,10,10]]},"references-count":24,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2020,10,10]]},"published-print":{"date-parts":[[2021,1,1]]}},"URL":"https:\/\/doi.org\/10.1093\/ajhp\/zxaa328","relation":{},"ISSN":["1079-2082","1535-2900"],"issn-type":[{"value":"1079-2082","type":"print"},{"value":"1535-2900","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2021,1,1]]},"published":{"date-parts":[[2020,10,10]]}}}